| Name | Title | Contact Details |
|---|
Turner Surety and Insurance Brokerage, Inc. (TSIB) is a full-service brokerage that specializes in controlled insurance programs and traditional property and casualty placements. The company focuses on construction risk management, serving owners, developers, and contractors. TSIB has extensive experience in managing construction risks, particularly through Controlled Insurance Programs (CIPs) and Owner-Controlled Insurance Programs (OCIPs), ensuring effective risk management and safety controls. TSIB has worked on over 450 healthcare projects, totaling more than $20 billion in construction volume. They offer customized insurance programs and reinsurance solutions, supporting the Managing General Agent (MGA) community. Their services also include consulting for professional services, surety programs, and various health-related benefits. TSIBs expertise in Wrap-Up programs helps manage construction projects comprehensively, from orientation to financial auditing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MISSION STATEMENT The mission of San Diego Opera is to deliver exceptional vocal performances and exciting, accessible programs to diverse audiences, focusing on community engagement and the transformative power of live performance. VISION STATEMENT The San Diego Opera will be recognized internationally as a leading example of adaptability, innovation and sustainability in the operatic arts, promoting diversified programming and unique performance venues with world-class and emerging talent. CORE VALUES STATEMENT - Through excellence in innovative programming and education, San Diego Opera provides a lasting cultural service to the community. - Our tradition of excellence in fully staged opera is augmented with new models of opera and venues. Our unique and deep commitment to the community propels us to explore ways of increasing affordability and accessibility. - Through fiscal responsibility and nimble adaptation to the changing marketplace, we protect the future of San Diego Opera. - Our educational and community involvement coupled with relevant programming will build the audience of the future.
ADB primarily provides specialized financial intermediation and related services with the objective of promoting a sustained and diversified agricultural and rural development as a foundation for the countrys over all development .In addition, to cultivate effective linkages between the agricultural sector and the rest of the economy and to complement the provision of banking services through out the country, ADB also provides ordinary commercial banking services , as well as servicing other sectors of the economy.